Ardelyx (NASDAQ:ARDX) Shares Gap Down After Earnings Miss

Key Points

• Stock reaction / EPS miss: Ardelyx shares gapped down pre-market after reporting a Q1 GAAP loss of $0.15 per share versus the consensus loss of $0.13, missing estimates by $0.02.
• Top-line strength and guidance: Revenue beat at $94.47M (vs. $92.78M est.) and rose 27.5% YoY with IBSRELA sales up ~58% YoY; management reiterated 2026 revenue guidance of $410–$430M and a cash balance of roughly $238M.
• Profitability and sentiment mix: The company still shows negative profitability (net margin -15.12%, ROE -40.63%) and insiders have sold shares recently, while analysts maintain a "Moderate Buy" consensus (avg. target ~$15.70) and a recent spike in call buying suggests short‑term bullish trader interest.

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report)'s stock price gapped down prior to trading on Friday following a dissappointing earnings announcement. The stock had previously closed at $6.33, but opened at $6.00. Ardelyx shares last traded at $6.5010, with a volume of 1,889,510 shares traded.

The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $94.47 million for the quarter, compared to the consensus estimate of $92.78 million. Ardelyx had a negative net margin of 15.12% and a negative return on equity of 40.63%. Ardelyx's quarterly revenue was up 27.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.17) EPS.

Key Ardelyx News

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Q1 revenue and product growth beat expectations: total revenue (~$94.5M) and product revenue (~$93.4M) rose strongly year‑over‑year, with IBSRELA sales up ~58% YoY; management reiterated 2026 revenue guidance of $410–$430M and reported a healthy cash balance (~$238M), supporting commercialization and runway. Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Unusual options flow: a large spike in call buying (7,048 calls, ~267% above typical volume) signals short‑term bullish sentiment from traders/hedgers, which can amplify upside momentum in the shares.
• Neutral Sentiment: Management emphasized strategic investments and commercialization execution on the earnings call — uses of cash and investment pacing matter for near‑term profits but aim to drive longer‑term growth. Ardelyx Inc (ARDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments
• Neutral Sentiment: The full earnings call transcript provides detail on channel trends, international plans and R&D spend — useful for investors assessing sustainability of revenue and timing of margin improvement. Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
• Negative Sentiment: EPS missed estimates: GAAP loss of $0.15/sh vs. consensus loss of $0.13, and the company still reports negative net margin and ROE; continuing operating losses keep near‑term profitability uncertain and may limit analyst upgrades. Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates
• Negative Sentiment: Despite top‑line strength, the EPS miss and negative profitability metrics mean upside depends on continued sales acceleration, margin improvement and execution vs. guidance; any slowdown could pressure the share price. Ardelyx: Q1 Earnings Snapshot

Analyst Upgrades and Downgrades

ARDX has been the subject of several research analyst reports. Williams Trading set a $17.00 price objective on Ardelyx in a research note on Thursday, March 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Ardelyx in a research note on Monday, April 20th. TD Cowen reaffirmed a "buy" rating on shares of Ardelyx in a research note on Thursday, January 29th. Leerink Partners reaffirmed an "outperform" rating on shares of Ardelyx in a research note on Thursday, March 12th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $15.00 price target on shares of Ardelyx in a research note on Tuesday, January 27th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $15.70.

Insider Buying and Selling

In other news, CEO Michael Raab sold 41,666 shares of the business's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $5.84, for a total value of $243,329.44. Following the completion of the sale, the chief executive officer owned 1,816,448 shares of the company's stock, valued at approximately $10,608,056.32. The trade was a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eric Duane Foster sold 10,439 shares of the business's stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $5.85, for a total value of $61,068.15. Following the transaction, the insider owned 425,970 shares in the company, valued at approximately $2,491,924.50. This represents a 2.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 128,604 shares of company stock worth $751,917 in the last 90 days. 4.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of Ardelyx by 14.6% during the 3rd quarter. Vanguard Group Inc. now owns 18,369,321 shares of the biopharmaceutical company's stock worth $101,215,000 after acquiring an additional 2,337,672 shares during the period. Y Intercept Hong Kong Ltd grew its holdings in shares of Ardelyx by 488.0% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 306,547 shares of the biopharmaceutical company's stock worth $1,689,000 after acquiring an additional 254,417 shares during the period. AIGH Capital Management LLC purchased a new position in shares of Ardelyx during the 3rd quarter worth approximately $1,094,000. SG Americas Securities LLC grew its holdings in shares of Ardelyx by 514.6% during the 3rd quarter. SG Americas Securities LLC now owns 131,925 shares of the biopharmaceutical company's stock worth $727,000 after acquiring an additional 110,459 shares during the period. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in shares of Ardelyx by 23.0% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 959,540 shares of the biopharmaceutical company's stock worth $5,594,000 after acquiring an additional 179,192 shares during the period. Hedge funds and other institutional investors own 58.92% of the company's stock.

Ardelyx Price Performance

The business has a fifty day simple moving average of $6.02 and a two-hundred day simple moving average of $6.14. The company has a current ratio of 4.31, a quick ratio of 4.11 and a debt-to-equity ratio of 1.21. The stock has a market cap of $1.65 billion, a PE ratio of -26.71 and a beta of 0.66.

Ardelyx Company Profile

Ardelyx, Inc NASDAQ: ARDX is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company's lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx's proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx's development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.